Full Press Release Details
One University Plaza, Suite
307 Hackensack, NJ 07601 Tel: 201-808-8400
CHAMPIONS ONCOLOGY REPORTS RESIGNATION
August 3, 2012 - Champions Oncology, Inc.
(OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development
and use of oncology drugs , today announced that James Martell has resigned from the Company's Board of Directors. Mr. Martell,
who started the company in 1985 as a sports-theme restaurant franchise under the name "Champions Sports, Inc." and
has remained on the board through its conversion to a cancer technology company, has resigned to pursue other business opportunities.
"Jim has been a valuable resource and advisor at Champions
Oncology", commented Joel Ackerman, Champions Oncology CEO. "We wish him much success in his new endeavors."
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of advanced
technology solutions and services to personalize the development and use of oncology drugs. The Company's Tumorgraft Technology
Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient
mice followed by propagation of the resulting engraftments, or Tumorgrafts, in a manner that preserves the biological characteristics
of the original human tumor. The Company uses this technology in conjunction with related services to offer solutions for two customer
groups: Personalized Oncology Solutions ("POS") in which physicians and patients looking for information help guide
the development of personalized treatment plans, and Translational Oncology Solutions ("TOS") in which pharmaceutical
and biotech companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing
new drugs and increasing the adoption of existing drugs. The Company's Tumorgraft Technology Platform consists of processes,
physical tumors and information that we use to personalize the development and use of oncology drugs. The Company is building its
Tumorgraft Technology Platform through the procurement, development and characterization of numerous Tumorgrafts within each of
several cancer types. Tumorgrafts are procured through agreements with a number of institutions in the U.S. and overseas as well
as through its POS business. The Tumorgrafts are developed and tested in the Company's laboratory facility in Baltimore,
Our POS business offers physicians and patients information
to help guide the development of personalized treatment plans. Our core offering utilizes our technology platform to empirically
test the response of a patient's tumor to multiple oncology drugs or drug combinations. The process begins by implanting
a fresh fragment of the patient's tumor, typically received within 24 hours of surgery or biopsy, in a small colony of immune-deficient
mice to grow the tumor tissue. This colony is then expanded by implanting the grown tumor tissue into subsequent generations of
mice until a sufficient number of mice are available for testing. At that point, the colony is allocated to different groups, and
each mouse in a group is dosed with a different drug or drug combination. The response of the tumor in each mouse is tracked over
time and analyzed to determine which drug or drug combination is providing the highest level of tumor growth inhibition. Our data
demonstrates that there is a high correlation between the response to drugs of the tumor in mice with the response of the tumor